乌拉地尔治疗老年慢性肺心病心衰的疗效观察  

Curative Effect of Urapidil for Senile Chronic Pulmonary Heart Disease with Heart Failure

作　　者：江玉玲[1] 李霞[1] 

机构地区：[1]河南信阳职业技术学院附属医院,464000

出　　处：《实用全科医学》2006年第2期172-173,共2页Applied Journal Of General Practice

摘　　要：目的观察乌拉地尔注射液治疗老年慢性肺源性心脏病的疗效.方法选择我院2001年3月～2004年6月临床确诊的老年慢性肺心病心衰共100例,随机分为两组,乌拉地尔观察组50例和酚妥拉明对照组50例,疗程均为10 d.结果观察组的总有效率86%,对照组为72%,两组总有效率比较,观察组疗效明显优于对照组（P＜0.05）.平均肺动脉压（mPAP）在观察组由（5.19±1.20）kPa下降至（3.74±0.74）kPa（P＜0.01）,对照组由（4.97±0.74）kPa下降至（4.37±0.82）kPa（P＜0.01）,观察组治疗后较对照组治疗后mPAP下降更明显,两组间差异有显著性（P＜0.01）.结论乌拉地尔可扩张肺动脉,降低肺动脉压（PAP）,促进心功能改善,提高生活质量,在老年慢性肺心病心衰的治疗中疗效确切.Objective To investigate the curative effect of Urapidil injection for the senile chronic pulmonary heart disease with heart failure. Methods 100 cases of the senile chronic pulmonary heart disease with heart failure were randomly divided into two groups （ n = 50） ： experiment group were treated with Urapidil Injection and control group treated with Phentolarnine Injection. The period of treatment was 10 days. Results The effective rate is 86% in the experiment group and 72% in the control group. The total effective rate of experiment group was higher than control group obviously （P〈 0.05）. Mean pulmonary artery pressure（mPAP） decreased from（5.19±1.20）kPa to （3.47 ±0.74）kPa in the treatment group （P〈0.1）, and from （4.97 ±0.74）kPa to （4.37±0.82）kPa in the control group （P〈 0.01 ）. The mPAP in the treatment group decreased more than that in the control group. The difference between the two groups was significantly （P〈 0.01 ）. Conclusions Urapidil can dilate pulmonary artery, reduce the mPAP, and improve cardiac function and the life quality. The curative effect of Urapidil in senile chronic pulmonary heart disease with heart failure is exact.

关 键 词：肺源性心脏病 心力衰竭 乌拉地尔 

分 类 号：R541.5[医药卫生—心血管疾病]